Etenarcept biosimilar has proved to be a great therapeutical option in patients affected by moderate-severe psoriasis. Both efficacy and safety profile -in our real life study- showed the same profile of the originator.
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry / Gisondi P.; Bianchi L.; Calzavara-Pinton P.; Conti A.; Chiricozzi A.; Fimiani M.; Pellegrino M.; Giunta A.; Prignano F.; Tiberio R.; Venturini M.; Girolomoni G.. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - ELETTRONICO. - 180:(2019), pp. 409-410. [10.1111/bjd.17133]
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry
Fimiani M.;Pellegrino M.;Giunta A.;Prignano F.;Tiberio R.;
2019
Abstract
Etenarcept biosimilar has proved to be a great therapeutical option in patients affected by moderate-severe psoriasis. Both efficacy and safety profile -in our real life study- showed the same profile of the originator.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
